Table 4. HPV16 physical status and level of pSTAT3 expression in cervical precancer and cancer lesions.
| Tissue Type | pSTAT3 Levels | Physical State of HPV16 Genome | Total (%) | p-value* | ||
|---|---|---|---|---|---|---|
| Episomal (%) (E2:E6 ≥ 1.0) |
Mixed (%) (0 < E2:E6 > 1.0) |
Integrated (%) (E2:E6 = 0) | ||||
|
LSIL (n = 30) |
Nil/Weak | 21 (70) | 3 (10) | - | 24 (80) | 0.361 |
| Moderate/Strong | 6 (20) | - | - | 6 (20) | ||
| HSIL | Nil/Weak | 11 (36) | 5 (17) | 2 (7) | 18 (60) | 0.603 |
| (n = 30) | Moderate/Strong | 6 (20) | 3 (10) | 3 (10) | 12 (40) | |
| SCC | Nil/Weak | 3 (4) | 5 (7) | 5 (7) | 13 (18) | <0.04 |
| (n = 70) | Moderate/Strong | 2 (3) | 24 (35) | 31 (44) | 57 (82) | |
|
Total (n = 130) |
Nil/Weak | 35 (27) | 13 (10) | 7 (5) | 55 (42) | <0.001a |
| Moderate/Strong | 14 (11) | 27 (21) | 34 (26) | 75 (58) | ||
LSIL—Tissues derived from Low-grade Squamous Intraepithelial Lesions; HSIL—Tissues derived from High-grade Squamous Intraepithelial Lesions; SCC—Tissues derived from Squamous Cell Carcinoma; SE–Standard Error
aPearson Chi-square p<0.001between two levels of STAT3 expression concerning the three different physical status of HPV16.
*Bold type refers to statistically significant p values.